Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their ...

The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater with dupilumab vs. placebo, according to findings from a win ratio analysis ...